ES2171768T3 - Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina. - Google Patents

Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.

Info

Publication number
ES2171768T3
ES2171768T3 ES97103712T ES97103712T ES2171768T3 ES 2171768 T3 ES2171768 T3 ES 2171768T3 ES 97103712 T ES97103712 T ES 97103712T ES 97103712 T ES97103712 T ES 97103712T ES 2171768 T3 ES2171768 T3 ES 2171768T3
Authority
ES
Spain
Prior art keywords
resortion
vitronectine
osea
inhibitors
receptors antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97103712T
Other languages
English (en)
Inventor
Volkmar Wehner
Jochen Knolle
Hans Ulrich Stilz
Denis Carniato
Jean-Francois Gourvest
Tom Gadek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Genentech Inc
Original Assignee
Hoechst AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1996126701 external-priority patent/DE19626701A1/de
Priority claimed from DE1996135522 external-priority patent/DE19635522A1/de
Application filed by Hoechst AG, Genentech Inc filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2171768T3 publication Critical patent/ES2171768T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/52—Nitrogen atoms not forming part of a nitro radical with hetero atoms directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/18—Nitrogen atoms not forming part of a nitro radical with hetero atoms attached to said nitrogen atoms, except nitro radicals, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

EL OBJETO DE LA PRESENTE INVENCION SON HETEROCICLOS DE CINCO MIEMBROS CON LA FORMULA GENERAL I, DONDE E, F, G, W, Y Y Z TIENEN EL SIGNIFICADO INDICADO EN LAS REIVINDICACIONES DE LA PATENTE, ASI COMO SU PREPARACION Y SU UTILIZACION COMO MEDICAMENTOS. LOS COMPUESTOS DE LA INVENCION SE UTILIZAN COMO ANTAGONISTAS DEL RECEPTOR DE LA VITRONECTINA Y COMO INHIBIDORES DE LA RESORCION OSEA.
ES97103712T 1996-03-20 1997-03-06 Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina. Expired - Lifetime ES2171768T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19610919 1996-03-20
DE1996126701 DE19626701A1 (de) 1996-07-03 1996-07-03 Neue Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE1996135522 DE19635522A1 (de) 1996-09-02 1996-09-02 Neue Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten

Publications (1)

Publication Number Publication Date
ES2171768T3 true ES2171768T3 (es) 2002-09-16

Family

ID=27216049

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97103712T Expired - Lifetime ES2171768T3 (es) 1996-03-20 1997-03-06 Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.

Country Status (24)

Country Link
US (3) US6218415B1 (es)
EP (1) EP0796855B1 (es)
JP (1) JP4546584B2 (es)
KR (1) KR970065523A (es)
CN (1) CN1072647C (es)
AR (1) AR006273A1 (es)
AT (1) ATE212990T1 (es)
AU (1) AU715729B2 (es)
BR (1) BR9701335A (es)
CA (1) CA2199923A1 (es)
CZ (1) CZ289696B6 (es)
DE (1) DE59706273D1 (es)
DK (1) DK0796855T3 (es)
ES (1) ES2171768T3 (es)
HR (1) HRP970156A2 (es)
HU (1) HUP9700602A3 (es)
IL (1) IL120479A (es)
MX (1) MX9702070A (es)
NO (1) NO314547B1 (es)
NZ (1) NZ314433A (es)
PL (1) PL319071A1 (es)
PT (1) PT796855E (es)
SK (1) SK35097A3 (es)
TW (1) TW363064B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE212990T1 (de) 1996-03-20 2002-02-15 Hoechst Ag Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten
US5981546A (en) * 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
US5952341A (en) * 1996-10-30 1999-09-14 Merck & Co., Inc. Integrin antagonists
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
DE19647382A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647380A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
DE19653645A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
DE19653647A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6017925A (en) * 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
EP1047425A4 (en) * 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
US6211191B1 (en) 1997-12-17 2001-04-03 Merck & Co., Inc. Integrin receptor antagonists
US6066648A (en) 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
WO1999052872A1 (en) 1998-04-09 1999-10-21 Meiji Seika Kaisha, Ltd. AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS
WO1999052879A1 (en) * 1998-04-14 1999-10-21 American Home Products Corporation Acylresorcinol derivatives as selective vitronectin receptor inhibitors
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
WO2000038715A2 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
WO2000047207A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE60035779T2 (de) 1999-06-02 2008-04-30 Merck & Co., Inc. Alpha v integrin-rezeptor antagonisten
EP1198231A1 (en) 1999-07-21 2002-04-24 American Home Products Corporation Bicyclic antagonists selective for the(alpha)v(beta)3 integrin
EP1209152A4 (en) 1999-08-05 2003-03-12 Meiji Seika Kaisha OMEGA-AMINO-ALPHA-HYDROXY-CARBONIC ACID DERIVATIVES WITH AN INTEGRIN ALPHA V BETA ANTAGONISM
EP1229910A4 (en) * 1999-10-04 2003-10-01 Merck & Co Inc integrin
WO2001053297A1 (en) 2000-01-20 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
EP1620092A4 (en) * 2003-05-07 2008-04-16 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2007089335A2 (en) * 2005-12-29 2007-08-09 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
US20080051335A1 (en) * 2006-05-02 2008-02-28 Kleiner Lothar W Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers
US8865909B2 (en) * 2008-11-20 2014-10-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-biofilm agents
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2017167622A1 (en) 2016-03-30 2017-10-05 Basf Se Process for the flash calcination of a zeolitic material
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
PT3844162T (pt) 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
US11478466B2 (en) 2019-04-01 2022-10-25 Cornell University Small molecule promoting osteoblast differentiation
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3044236A1 (de) 1980-11-25 1982-06-16 Hoechst Ag, 6000 Frankfurt Aminosaeurederivate und verfahren zu ihrer herstellung
DE2937779A1 (de) 1979-09-19 1981-04-09 Hoechst Ag, 6000 Frankfurt Aminosaeurederivate und verfahren zu ihrer herstellung
FR2503155A2 (fr) 1980-10-02 1982-10-08 Science Union & Cie Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
FR2487829A2 (fr) 1979-12-07 1982-02-05 Science Union & Cie Nouveaux imino acides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
US4350704A (en) 1980-10-06 1982-09-21 Warner-Lambert Company Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids
DE3177130D1 (de) 1980-08-30 1990-01-11 Hoechst Ag Aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung.
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
FR2492381A1 (fr) 1980-10-21 1982-04-23 Science Union & Cie Nouveaux acides aza bicyclo alcane carboxyliques substitues leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
LU88621I2 (fr) 1980-10-23 1995-09-01 Schering Corp Sandopril
US4374847A (en) 1980-10-27 1983-02-22 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
DE3226768A1 (de) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
NZ202903A (en) 1981-12-29 1988-01-08 Hoechst Ag 1-- pe pyrrol-2-yl-carboxylic acid derivatives and pharmaceutical compositions
DE3210496A1 (de) 1982-03-23 1983-10-06 Hoechst Ag Neue derivate bicyclischer aminsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung
DE3211397A1 (de) 1982-03-27 1983-11-10 Hoechst Ag, 6230 Frankfurt Spiro (4.(3+n))-2-aza-3-carbonsaeure-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
DE3211676A1 (de) 1982-03-30 1983-10-06 Hoechst Ag Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
DE3227055A1 (de) 1982-07-20 1984-01-26 Hoechst Ag, 6230 Frankfurt Neue derivate der 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure als zwischenstufe und verfahren zu deren herstellung
DE3242151A1 (de) 1982-11-13 1984-05-17 Hoechst Ag, 6230 Frankfurt Neue derivate tricyclischer aminosaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung, sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung
DE3246503A1 (de) 1982-12-16 1984-06-20 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(5.3.0)-decan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3643012A1 (de) 1986-12-17 1988-06-30 Hoechst Ag 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
DE3818850A1 (de) 1988-06-03 1989-12-07 Hoechst Ag Oligopeptide mit zyklischen prolin-analogen aminosaeuren
DE4009506A1 (de) 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
JPH04367367A (ja) 1991-06-11 1992-12-18 Nkk Corp ロータリノズル
DE4126277A1 (de) 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
US5217994A (en) * 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
DE4207254A1 (de) 1992-03-07 1993-09-09 Cassella Ag 4-oxo-2-thioxoimidazolidin-derivate
DE4213634A1 (de) 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate
DE4224414A1 (de) * 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
EP0667773A4 (en) 1992-10-14 1996-09-25 Merck & Co Inc FIBRINOGEN RECEPTOR ANTAGONISTS.
CA2150550A1 (en) 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
DE4301747A1 (de) * 1993-01-23 1994-07-28 Cassella Ag Substituierte Aminoverbindungen, ihre Herstellung und ihre Verwendung
DE4308034A1 (de) 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
DE4427979A1 (de) * 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
ATE227567T1 (de) 1994-05-27 2002-11-15 Merck & Co Inc Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
WO1996000730A1 (en) 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
ZA955391B (en) 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
TW449590B (en) * 1995-04-14 2001-08-11 Boehringer Ingelheim Kg New arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds
JP3895792B2 (ja) * 1995-12-08 2007-03-22 プロスケリア・エス・ア・エス 骨形成促進剤
ATE212990T1 (de) 1996-03-20 2002-02-15 Hoechst Ag Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten

Also Published As

Publication number Publication date
EP0796855A1 (de) 1997-09-24
US20020119999A1 (en) 2002-08-29
HK1017346A1 (en) 1999-11-19
KR970065523A (ko) 1997-10-13
AU1638097A (en) 1997-09-25
HUP9700602A1 (hu) 1998-03-30
IL120479A0 (en) 1997-07-13
BR9701335A (pt) 1998-08-18
DE59706273D1 (de) 2002-03-21
US6218415B1 (en) 2001-04-17
EP0796855B1 (de) 2002-02-06
NO971268D0 (no) 1997-03-19
JP4546584B2 (ja) 2010-09-15
SK35097A3 (en) 1997-10-08
HUP9700602A3 (en) 2000-04-28
NO314547B1 (no) 2003-04-07
DK0796855T3 (da) 2002-05-27
NZ314433A (en) 1999-03-29
CA2199923A1 (en) 1997-09-20
CN1072647C (zh) 2001-10-10
US20010021708A1 (en) 2001-09-13
CZ82397A3 (en) 1997-12-17
CZ289696B6 (cs) 2002-03-13
JPH09255664A (ja) 1997-09-30
TW363064B (en) 1999-07-01
PL319071A1 (en) 1997-09-29
PT796855E (pt) 2002-07-31
CN1206005A (zh) 1999-01-27
US6620820B2 (en) 2003-09-16
AU715729B2 (en) 2000-02-10
IL120479A (en) 2001-03-19
HRP970156A2 (en) 1998-04-30
HU9700602D0 (en) 1997-05-28
MX9702070A (es) 1998-03-31
AR006273A1 (es) 1999-08-11
ATE212990T1 (de) 2002-02-15
NO971268L (no) 1997-09-22

Similar Documents

Publication Publication Date Title
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
UY26482A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
PA8553101A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
ES2138977T3 (es) Agonistas muscarinicos.
ATE516305T1 (de) Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten
ES2196072T3 (es) Empleo de compuestos heterociclicos como ligandos de dopamina-d3.
MX9207074A (es) Piperazinil- y piperidinil -ciclohexanoles y composicion farmaceutica que los comprende
ECSP941156A (es) 3 bencilaminometil piperidinas substituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
GT199900008A (es) Compuestos 4-(2-ceto-1-benzilimidazolinil) piperidina como agonistas del receptor orl1
UY27760A1 (es) Nuevos derivados de pirrolidinio.
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
NO960630L (no) Heterocykler anvendelige som neurokinin antagonister
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
IT1313625B1 (it) Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
CO4910133A1 (es) Antagonistas de 5-h[1f]
PA8543201A1 (es) DERIVADOS DE DIHIDRO-BENZO [B] [1,4]-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGluR2
AR010369A1 (es) Antagonista de receptor vitronectina, su preparacion asi como su empleo.
ES2213707T3 (es) Estimulacion del crecimiento oseo con un derivado peptidico de la trombina.
ES2150039T3 (es) Benzonitrilos como 5-ht agonistas y antagonistas.
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
PA8556701A1 (es) Derivados del 3-azabiciclo(3.1.0)hexano
DK1129091T3 (da) Antagonister for CRF-receptorer og fremgangsmåder med relation dertil
MA26933A1 (fr) Derives de 4-phenyl-pyridine en tant qu'antagonistes de recepteur de la neurokinine 1.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 796855

Country of ref document: ES